2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Emerging Technologies, Treatment Considerations, Supportive Care, Biological Therapies, Infusion, Non-Biological Therapies, Anticoagulant Drugs, Coagulant Drugs, Pharmacology, Women’s Health, Workforce, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, VWD, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Neutropenia, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Pregnant, Young Adult
PAPER

2620 Trends and appropriateness of prothrombin complex concentrate (PCC) use in hamilton, Canada: A retrospective analysis over an 8-year period

Darsh Shah, MD, Ashlyn Chou2, Katherine Li3, Michele Perry, MLT4, Menaka Pai, MSc, MD, FRCPC5, Sam Schulman, Professor6, Mark Crowther, MD MSc7, Ali Eshaghpour, MD8, Siraj Mithoowani, MD, MHPE, FRCPC, FACP9
1 McMaster University, Hamilton, Ontario, Canada
2 McMaster University, Hamilton, Ontario, Canada
3 McMaster University, Hamilton, Ontario, Canada
4 Hamilton Health Sciences, Hamilton, Canada
5 Hamilton Health Sciences, Hamilton, Canada, McMaster University, Hamilton, Ontario, Canada, McMaster University, Hamilton, Ontario, Canada
6 McMaster University, Hamilton, Ontario, Canada
7 McMaster University, Hamilton, Ontario, Canada
8 McMaster University, Hamilton, Ontario, Canada
9 McMaster University, Hamilton, Ontario, Canada

Prothrombin complex concentrate (PCC) is hemostatic agent commonly used off-label for patients on direct oral anticoagulants (DOACs) with major bleeding or who require urgent surgery. Despite its widespread use, evidence supporting the efficacy of PCC for DOAC reversal remains limited and few real-world data have evaluated the appropriateness and safety of PCC in this setting. PCC is associated with a 4-8% short-term risk of thromboembolism in observational studies, and therefore, its overuse could be harmful. Our primary aim was to characterize indications for PCC administration across two tertiary care hospital systems in Hamilton, Canada over 8 years. Our secondary aim was to evaluate the appropriateness and safety of PCC used for major bleeding or urgent surgery in patients receiving DOACs.

            We report a subset of our planned retrospective cohort consisted of all adult patients at two tertiary care hospitals in Hamilton, Canada who received PCC for any indication between August 2018 and December 2025. Eligible patients were identified by hospital information technology analysts and cross-referenced with a local transfusion medicine database. PCC dose, indication, and setting were recorded for all patients. Among patients on DOACs, we extracted additional data including the type and dose of DOAC, indication for PCC (major bleeding or urgent surgery), demographic and laboratory parameters, and other hemostatic interventions. The appropriateness of PCC administration was adjudicated using the Canadian National Advisory Committee (NAC) guideline for PCC use. Major bleeding was defined as per International Society on Thrombosis and Haemostasis (ISTH) criteria, and urgent surgery was defined as any procedure required within six hours to preserve life or limb. Safety outcomes were venous or arterial thrombosis and all-cause mortality within 30 days. Data were summarized descriptively. The study was approved by the Hamilton Integrated Research Ethics Board.

From a preliminary analysis of records between August 2018 and June 2022, we identified 1003 PCC administrations across two hospital sites. There was a median of 22 (IQR 8) monthly administrations. PCC was most used in the emergency department (42.6%), ICU (24.3%), and ward (21.3%). The modal dose was 2,000 international units (IU), and the range was 500-4,000 IU.

Thus far, additional data have been extracted from a random sample of 111 patients between August 2018 and June 2022. Indications for PCC were major bleeding (n=55, 49.5%), urgent surgery (n=39, 35.1%) and other (n=17, 15.3%), including semi-urgent and bedside procedures. Patients were most commonly on warfarin (n=59, 53.2%) and DOACs (n=46, 41.4%). Five patients (4.5%) were not on anticoagulation, and one patient (0.9%) was on low molecular weight heparin.

Among patients on DOACs, 25/26 (96.2%) administrations of PCC for major bleeding and 10/16 (62.5%) administrations of PCC for urgent procedures were consistent with NAC guidelines. Among the six instances of non-adherent urgent procedure administrations, one was not for preservation of life or limb, two did not occur within six hours of surgery, and three met neither criterion. Twelve of 46 patients on DOACs also received vitamin K and/or fresh frozen plasma (FFP). A factor Xa level was drawn on the day of PCC administration for 14/46 patients on DOAC therapy. Seven of 14 patients (50.0%) had a DOAC level below 75 ng/mL prior to PCC administration.

Among the 41 DOAC-treated patients alive at 30 days, 33 (80.5%) patients resumed anticoagulation at 30 days: prophylactic anticoagulation only (n=14, 34.1%), therapeutic anticoagulation only (n=4, 9.8%%), or prophylactic followed by therapeutic anticoagulation (n=15, 36.6%). The median time to initiating prophylactic anticoagulation was 2.3 days (IQR 1.1–4.9), while the median time to initiating therapeutic anticoagulation was 5.9 days (IQR 4.5–11.8). For the 111 patients reviewed, all-cause mortality and objectively confirmed thrombosis after PCC at 30 days occurred in 20 (18.2%) and 6 (5.6%) patients respectively.

In this interim analysis, PCC was commonly used off-label for DOAC reversal. Among patients on DOACs, PCC use for major bleeding was largely guideline-concordant, but often guideline-discordant for urgent procedures, highlighting an opportunity to improve stewardship. Data collection is ongoing to provide a more comprehensive assessment of the appropriateness and safety of PCC in our cohort.

Ali Eshaghpour, MD: No relevant conflicts of interest to declare.